Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Obama pitches his health care plan on Funny or Die
11 Mar 2014 at 7:15pm
NEW YORK (AP) ? Zach Galifianakis brought the ferns, and President Barack Obama opened a new avenue of presidential communication.
Gene mapping study shows promise, challenges
11 Mar 2014 at 1:14pm
CHICAGO (AP) ? These days, it's faster and cheaper than ever to decipher a person's entire DNA. But a small study suggests that looking for disease risks that way may not be ready for the masses.
Study: 2 percent of Americans have new hips, knees
11 Mar 2014 at 12:51am
It's not just grandma with a new hip and your uncle with a new knee. More than 2 of every 100 Americans now have an artificial joint, doctors are reporting.
Republican Party wins Florida congressional seat in special election
11 Mar 2014 at 8:01pm
By Barbara Liston ORLANDO, Florida (Reuters) - Republican David Jolly won an expensive battle to fill a vacant U.S. Congressional seat in a special election watched by both major parties for what it portends for November when all 435 congressional seats will be up for grabs. Jolly, 41, defeated Democrat challenger Alex Sink, 65, a former state chief financial officer, by 3,500 votes or a 1.87 percent margin - 48.43 percent to 46.56 percent, according to the Pinellas County Supervisor of Elections website. Libertarian candidate Lucas Overby took 4.83 percent of the votes. Republicans were quick to declare the result a repudiation of President Obama's Affordable Healthcare Act, known as Obamacare.
Louisiana man fined $600 after drunken fight with wife aboard flight
11 Mar 2014 at 6:06pm
A judge in the Cayman Islands fined a Louisiana man $600 on Tuesday for forcing a Delta Air Lines flight to make an emergency landing after he got into a drunken argument with his wife aboard the plane on their anniversary. Michael Foret, 33, was escorted from a Delta Air Lines plane by police when it landed in the Cayman Islands on Sunday night. On Tuesday, Foret, who had been held in police custody, appeared before a Cayman Islands judge, his lawyer, Ben Tonner, said. Foret was fined for disruptive behavior aboard a commercial flight, he said.
Obamacare enrollment in private coverage rises to 4.2 million people
11 Mar 2014 at 3:39pm
By David Morgan WASHINGTON (Reuters) - The Obama administration said on Tuesday that 4.2 million people have signed up for private health insurance under Obamacare, and indicated that total enrollment could surpass a 6 million-enrollee forecast by the end of March. New enrollment data for a five-month period from October 1 through March 1 came out as the administration threw its public relations campaign into overdrive, with President Barack Obama appearing for an interview on the comedy website, "Funny or Die," in a direct appeal to the site's audience of young adults. ...
Insurers wary of Obamacare unknowns as they plan for 2015
11 Mar 2014 at 2:40pm
By Caroline Humer NEW YORK (Reuters) - U.S. health insurers are struggling to set prices for their Obamacare plans in 2015 and decide which regions to return to before the deadlines for submitting those plans to regulators. Some insurers already expect to lose money this year following the rocky launch of President Barack Obama's Affordable Care Act, which aims to provide coverage to millions of uninsured Americans with the help of government subsidies. ...
When Zach met Barack: pitching Obamacare online
11 Mar 2014 at 2:23pm
By Mark Felsenthal WASHINGTON (Reuters) - President Barack Obama took his quest to sign young people up for health insurance to an edgy comedy website on Tuesday, where he traded insults with host Zach Galifianakis while plugging his signature Obamacare health program. Obama sat for an interview on "Between Two Ferns with Zach Galifianakis," on the Funny or Die website. The actor, who starred in "The Hangover" films, is known for his cringe-inducing banter on the program. ...
Watch: Alleged Child Sex Assault Victim to Testify in Michigan
11 Mar 2014 at 2:05pm
Social worker explains why testifying in court could compound the 6-year-old's trauma.
FDA approves electric headband to prevent migraine
11 Mar 2014 at 2:03pm
WASHINGTON (AP) ? The Food and Drug Administration said Tuesday it approved a nerve-stimulating headband as the first medical device to prevent migraine headaches.
Especially for women, hearing loss linked to depression
11 Mar 2014 at 1:57pm
Higher rates of depression were most common among women and among the middle aged, compared to people over 70, researchers found. A few smaller studies have shown a connection between hearing loss and depression, but they were not based on nation-wide samples and the results were conflicting, Dr. Chuan-Ming Li said.
Profit-taking drags Wall Street lower
11 Mar 2014 at 1:54pm
By Rodrigo Campos NEW YORK (Reuters) - U.S. stocks fell on Tuesday, with selling picking up late in the session, as investors cashed in some of the recent market gains, but the S&P 500 finished less than 1 percent away from a record high set last week. Indexes had swung between gains and losses in the first half of the session, as the lack of major corporate earnings or market-affecting data kept trading directionless, but they closed near the day's lows. Shares of retailers American Eagle and Urban Outfitters fell sharply after disappointing outlooks. ...
Alleged Sex Assault Victim, 6, Too Young to Testify?
11 Mar 2014 at 1:45pm
Research shows that more sexual abuse cases are coming to light and children are increasingly being admitted as witnesses in court proceedings. An estimated 1.6 percent of children between the ages of 12-17 have been victims of rape/sexual assault and many must face their assailants.
Judge in Colorado theater massacre case appoints new sanity evaluator
11 Mar 2014 at 1:38pm
By Keith Coffman DENVER (Reuters) - A judge overseeing the Colorado movie theater massacre case appointed an evaluator on Tuesday to conduct a second sanity examination of accused gunman James Holmes after earlier ruling a first evaluation to be "incomplete and inadequate." Arapahoe County District Court Judge Carlos Samour, in a written ruling, approved the selection by the state mental hospital of the new examiner, whose name was redacted in the order. Holmes has pleaded not guilty by reason of insanity to murder and attempted murder charges linked to the 2012 shooting during a viewing of a Batman film in a suburban Denver cinema that killed 12 moviegoers and injured 70 others.
Oxigene Inc says drug meets main goal of ovarian cancer trial
11 Mar 2014 at 1:36pm
(Reuters) - Oxigene Inc said on Tuesday that its experimental drug Zybrestat combined with Roche's big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial. Shares of tiny Oxigene, which had been halted prior to announcement of the trial results, more than doubled in extended trading. The drugs, which use different mechanisms to deprive tumors of blood supply and oxygen needed to grow, met the primary goal of the study by demonstrating a statistically significant increase in progression-free survival (PFS), or the time it takes before the cancer begins to worsen. "This promising combination warrants further evaluation particularly given the significant need for new treatment options in relapsed ovarian cancer," Dr. Bradley Monk, lead investigator of the study, said in a statement.